These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35114509)

  • 21. Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma.
    Rondon L; Fu R; Patel MR
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).
    Rijavec E; Biello F; Barletta G; Dellepiane C; Genova C
    Mol Clin Oncol; 2022 Apr; 16(4):89. PubMed ID: 35251640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
    Katzman D; Sterman DH
    Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
    Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
    Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
    Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
    Remon J; Reguart N; Corral J; Lianes P
    Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
    Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma.
    Yun KM; Bazhenova L
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in Immunotherapy of Malignant Pleural Mesothelioma.
    Liao D; Yu Y; Mei Q; Wang Z; Li X; Jia Y; Kong F
    Onco Targets Ther; 2021; 14():4477-4484. PubMed ID: 34429612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging biological therapies for the treatment of malignant pleural mesothelioma.
    Davis AP; Kao SC; Clarke SJ; Boyer M; Pavlakis N
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):179-192. PubMed ID: 33945357
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapy in malignant pleural mesothelioma: a review of literature data.
    Menis J; Pasello G; Remon J
    Transl Lung Cancer Res; 2021 Jun; 10(6):2988-3000. PubMed ID: 34295692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
    Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
    Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
    Wright K
    Oncology (Williston Park); 2020 Nov; 34(11):502-503. PubMed ID: 33206991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repurposing therapeutics for malignant pleural mesothelioma (MPM) - Updates on clinical translations and future outlook.
    Kulkarni NS; Gupta V
    Life Sci; 2022 Sep; 304():120716. PubMed ID: 35709894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.
    Davis A; Ke H; Kao S; Pavlakis N
    Lung Cancer (Auckl); 2022; 13():1-12. PubMed ID: 35264891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
    Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC.
    Cantini L; Pecci F; Merloni F; Lanese A; Lenci E; Paoloni F; Aerts JGJV; Berardi R
    Explor Target Antitumor Ther; 2021; 2(1):1-25. PubMed ID: 36046087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.